Economic evaluation of hemodialysis: Implications for technology assessment in Greece

被引:34
|
作者
Kaitelidou, D
Ziroyanis, PN
Maniadakis, N
Liaropoulos, LL
机构
[1] Univ Athens, Ctr Hlth Serv Management & Evaluat, Dept Nursing, Athens 11527, Greece
[2] G Gennimatas Hosp, Dept Nephrol, Athens 11527, Greece
[3] Univ Hosp Rio, Rio Patra 26504, Greece
关键词
cost of hemodialysis; economic evaluation; cost of illness;
D O I
10.1017/S0266462305050051
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: Hemodialysis is a well-established treatment for 74 percent of end-stage renal disease (ESRD) patients in Greece. The purpose of this study is to provide an estimate of the direct cost of dialysis in a public hospital setting and an estimate of the loss of production for ESRD patients. The results will be useful for public health facility planning purposes. Methods: A socioeconomic prevalence-based analysis was performed using micro-economic evaluation of health-care resources consumed to provide hemodialysis for ESRD patients in 2000. Lost productivity costs due to illness were estimated for the patient and family using the human capital approach and the friction method. Indirect morbidity costs due to absence from work and long-term were estimated, as well as mortality costs. Mean gross income was used for both patient and family. Results: Total health-sector cost for hemodialysis in Greece exceeds Euro 171 million, or Euro 182 per session and Euro 229 per inpatient day. There were 2,046 years lost due to mortality, and the potential productivity cost was estimated at Euro 9.9 million, according to the human capital approach, and Euro 303.000, according to the friction method. Total morbidity cost due to absence from work and early retirement was estimated at more than Euro 273 million, according to the human capital approach, and Euro 12.5, according to the friction method. Conclusions: Providing hemodialysis care for 0.05 percent of the population suffering from ESRD absorbs approximately 2 percent of total health expenditure in Greece. In addition to the cost for the National Health System, production loss due to mortality and morbidity from the disease are also considerable. Promoting alternative technologies such as organ transplantation and home dialysis as well as improving hemodialysis efficiency through satellite units are strategies that may prove more cost-effective and psychologically advantageous for the patients.
引用
收藏
页码:40 / 46
页数:7
相关论文
共 50 条
  • [41] TIME TO HEALTH TECHNOLOGY ASSESSMENT OF NEW MEDICINAL PRODUCTS IN GREECE
    Chantzaras, A.
    Margetis, A.
    Kani, C.
    Koutsiouris, V
    Bacopoulou, F.
    VALUE IN HEALTH, 2022, 25 (12) : S342 - S342
  • [42] Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece
    Maniadakis, Nikos
    Ekman, Mattias
    Fragoulakis, Vasilios
    Papagiannopoulou, Vasiliki
    Yfantopoulos, John
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2011, 12 (03): : 253 - 261
  • [43] ECONOMIC EVALUATION OF RIVAROXABAN IN THE TREATMENT OF DEEP VEIN THROMBOSIS IN GREECE
    Kourlaba, G.
    Maniadakis, N.
    Giannoukas, A.
    Katsamouris, A.
    Katsenis, K.
    Lazarides, M.
    Matsagas, M.
    Lowin, J.
    McLeod, E. J.
    Bamber, L.
    VALUE IN HEALTH, 2012, 15 (07) : A372 - A372
  • [44] Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
    Georgia Kourlaba
    John Parissis
    Apostolos Karavidas
    Alexandra Beletsi
    Charalambos Milonas
    Neil Branscombe
    Nikos Maniadakis
    BMC Health Services Research, 14
  • [45] Methods of ecological and economic evaluation of technology
    Kowalski, Zygmunt
    Makara, Agnieszka
    CHEMIK, 2010, 64 (03): : 163 - 167
  • [46] Economic evaluation approaches for new technology
    Papatheofanis, FJ
    IEEE ENGINEERING IN MEDICINE AND BIOLOGY MAGAZINE, 2003, 22 (03): : 16 - 17
  • [47] Economic evaluation of ivabradine in the treatment of chronic heart failure in Greece
    Kourlaba, Georgia
    Parissis, John
    Karavidas, Apostolos
    Beletsi, Alexandra
    Milonas, Charalambos
    Branscombe, Neil
    Maniadakis, Nikos
    BMC HEALTH SERVICES RESEARCH, 2014, 14
  • [48] Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece
    Liaropoulos, L
    Spinthouri, M
    Ignatiades, T
    Ifandi, G
    Katostaras, F
    Diamantopoulos, E
    PHARMACOECONOMICS, 1998, 14 (05) : 575 - 588
  • [49] Economic evaluation of trimetazidine in the management of chronic stable angina in Greece
    Kourlaba, Georgia
    Gourzoulidis, George
    Andrikopoulos, George
    Tsioufis, Konstantinos
    Beletsi, Alexandra
    Maniadakis, Nikos
    BMC HEALTH SERVICES RESEARCH, 2016, 16
  • [50] An economic evaluation model for concession on convention infrastructure projects in Greece
    Evangelos K. Christakos
    Glikeria Kalfakakou
    Operational Research, 2007, 7 (1) : 147 - 164